$EYPT
EyePoint Pharmaceuticals, Inc.

2013 Form 10-K Financial Statement

#000119312513382009 Filed on September 27, 2013

View on sec.gov

Income Statement

Concept 2013 2012 Q2 2012 Q1
Revenue $2.143M $699.0K $538.0K
YoY Change -39.22% -81.18% 49.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.170M $1.600M $1.760M
YoY Change 4.37% -26.27% 0.0%
% of Gross Profit
Research & Development $7.005M $1.410M $1.508M
YoY Change -0.48% -23.78% -13.33%
% of Gross Profit
Depreciation & Amortization $225.0K $280.0K $230.0K
YoY Change 18.42% -67.06% -72.94%
% of Gross Profit
Operating Expenses $14.17M $3.010M $3.265M
YoY Change -50.68% -25.12% -6.71%
Operating Profit -$12.03M -$2.310M -$2.727M
YoY Change -52.28% 650.0% -13.13%
Interest Expense $20.00K $10.00K $10.00K
YoY Change -90.48% -50.0% -97.06%
% of Operating Profit
Other Income/Expense, Net $14.00K $0.00 $11.00K
YoY Change -93.24%
Pretax Income -$12.02M -$2.300M -$2.716M
YoY Change -51.94% 693.1% -3.0%
Income Tax -$117.0K -$40.00K -$30.00K
% Of Pretax Income
Net Earnings -$11.90M -$2.262M -$2.686M
YoY Change -52.08% 1515.71% 0.04%
Net Earnings / Revenue -555.3% -323.61% -499.26%
Basic Earnings Per Share -$0.52
Diluted Earnings Per Share -$0.52 -$1.087M -$1.293M
COMMON SHARES
Basic Shares Outstanding 23.04M shares
Diluted Shares Outstanding 23.04M shares

Balance Sheet

Concept 2013 2012 Q2 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.30M $14.60M $16.50M
YoY Change -29.45% -39.42% -28.57%
Cash & Equivalents $6.900M $4.625M $6.375M
Short-Term Investments $3.400M $9.900M $10.10M
Other Short-Term Assets $1.600M $400.0K $400.0K
YoY Change 300.0% 0.0% 0.0%
Inventory
Prepaid Expenses
Receivables $600.0K $1.000M $1.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.50M $15.96M $17.90M
YoY Change -21.88% -37.09% -26.34%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K $335.0K $400.0K
YoY Change -33.33% 172.36% 300.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $100.0K $100.0K
YoY Change 100.0% 0.0% 0.0%
Total Long-Term Assets $3.700M $4.638M $4.900M
YoY Change -19.57% -78.67% -78.32%
TOTAL ASSETS
Total Short-Term Assets $12.50M $15.96M $17.90M
Total Long-Term Assets $3.700M $4.638M $4.900M
Total Assets $16.20M $20.60M $22.80M
YoY Change -21.36% -56.28% -51.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $700.0K $394.0K $300.0K
YoY Change 75.0% 20.12% 0.0%
Accrued Expenses $1.900M $608.0K $800.0K
YoY Change 216.67% -54.01% -11.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.300M $3.178M $2.600M
YoY Change 3.13% -36.84% 73.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.200M $3.800M $4.700M
YoY Change 36.84% -17.39% -43.37%
Total Long-Term Liabilities $5.200M $3.800M $4.700M
YoY Change 36.84% -17.39% -43.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.300M $3.178M $2.600M
Total Long-Term Liabilities $5.200M $3.800M $4.700M
Total Liabilities $8.500M $6.961M $7.300M
YoY Change 21.43% -28.09% -26.26%
SHAREHOLDERS EQUITY
Retained Earnings -$251.8M
YoY Change 10.94%
Common Stock $21.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.700M $13.64M $15.60M
YoY Change
Total Liabilities & Shareholders Equity $16.20M $20.60M $22.80M
YoY Change -21.36% -56.28% -51.39%

Cashflow Statement

Concept 2013 2012 Q2 2012 Q1
OPERATING ACTIVITIES
Net Income -$11.90M -$2.262M -$2.686M
YoY Change -52.08% 1515.71% 0.04%
Depreciation, Depletion And Amortization $225.0K $280.0K $230.0K
YoY Change 18.42% -67.06% -72.94%
Cash From Operating Activities -$8.745M -$1.840M -$2.140M
YoY Change -2.84% -247.2% 32.1%
INVESTING ACTIVITIES
Capital Expenditures $68.00K -$10.00K -$20.00K
YoY Change -83.21% -83.33% 100.0%
Acquisitions
YoY Change
Other Investing Activities $6.430M $100.0K $120.0K
YoY Change 536.63% -106.45% -104.72%
Cash From Investing Activities $6.358M $90.00K $110.0K
YoY Change 949.17% -105.59% -104.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.669M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.669M 0.000 0.000
YoY Change 3995.61% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -8.745M -1.840M -2.140M
Cash From Investing Activities 6.358M 90.00K 110.0K
Cash From Financing Activities 4.669M 0.000 0.000
Net Change In Cash 2.282M -1.750M -2.030M
YoY Change -127.56% 360.53% -134.35%
FREE CASH FLOW
Cash From Operating Activities -$8.745M -$1.840M -$2.140M
Capital Expenditures $68.00K -$10.00K -$20.00K
Free Cash Flow -$8.813M -$1.830M -$2.120M
YoY Change -6.3% -239.69% 31.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2551000
CY2011Q1 psdv Common Stock Warrant Exercise Price Per Share
CommonStockWarrantExercisePricePerShare
5.00
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
466000
CY2012Q3 psdv Common Stock Warrant Exercise Price Per Share
CommonStockWarrantExercisePricePerShare
2.50
CY2012Q4 dei Entity Public Float
EntityPublicFloat
27506000
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26791561 shares
CY2011Q4 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
4600000
CY2011Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4596000
CY2011Q4 psdv Finite Lived Intangible Assets Net Before Impairment
FiniteLivedIntangibleAssetsNetBeforeImpairment
19426000
CY2011Q4 psdv Enterprise Value
EnterpriseValue
4400000
CY2010Q2 us-gaap Stockholders Equity
StockholdersEquity
33041000
CY2010Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15514000
CY2011Q2 us-gaap Stockholders Equity
StockholdersEquity
37433000
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12912000
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20802592 shares
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20802592 shares
CY2012Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
608000
CY2012Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1923000
CY2012Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16000
CY2012Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
264431000
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
394000
CY2012Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
262000
CY2012Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28092000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3178000
CY2012Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
942000
CY2012Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
149000
CY2012Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
950000
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
13636000
CY2012Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2012Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1472000
CY2012Q2 us-gaap Deferred Revenue
DeferredRevenue
6000000
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251758000
CY2012Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2176000
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
21000
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20597000
CY2012Q2 us-gaap Liabilities
Liabilities
6961000
CY2012Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3783000
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
9946000
CY2012Q2 us-gaap Assets Current
AssetsCurrent
15959000
CY2012Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
9954000
CY2012Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2119000
CY2012Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
967000
CY2012Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24021000
CY2012Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29564000
CY2012Q2 us-gaap Assets
Assets
20597000
CY2012Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
14238000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4625000
CY2012Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2012Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2258000
CY2012Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4226000
CY2012Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2341000
CY2012Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
421000
CY2012Q2 us-gaap Other Assets
OtherAssets
77000
CY2012Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Provision For Loan Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses
511000
CY2012Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
572000
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
335000
CY2012Q2 psdv Total Deferred Tax Assets And Liabilities Gross
TotalDeferredTaxAssetsAndLiabilitiesGross
28092000
CY2012Q2 psdv Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
181000
CY2012Q2 psdv Cash Equivalents Fair Value Disclosure
CashEquivalentsFairValueDisclosure
4292000
CY2012Q2 psdv Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
8000
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23297011 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23297011 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1894000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
75000
CY2013Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2046000
CY2013Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
270415000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
456000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
671000
CY2013Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
288000
CY2013Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31030000
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3303000
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
920000
CY2013Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1252000
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
921000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
7700000
CY2013Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2013Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1177000
CY2013Q2 us-gaap Deferred Revenue
DeferredRevenue
5600000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-263658000
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
738000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
23000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16249000
CY2013Q2 us-gaap Liabilities
Liabilities
8549000
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
18000
CY2013Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5246000
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
363000
CY2013Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3374000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
12464000
CY2013Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
3375000
CY2013Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2589000
CY2013Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
597000
CY2013Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
26068000
CY2013Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32207000
CY2013Q2 us-gaap Assets
Assets
16249000
CY2013Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
9704000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6899000
CY2013Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2013Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
6300000
CY2013Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2225000
CY2013Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3430000
CY2013Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2196000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1594000
CY2013Q2 us-gaap Other Assets
OtherAssets
176000
CY2013Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Provision For Loan Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses
511000
CY2013Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
843000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
179000
CY2013Q2 psdv Weighted Average Maturity
WeightedAverageMaturity
3.65 M
CY2013Q2 psdv Total Deferred Tax Assets And Liabilities Gross
TotalDeferredTaxAssetsAndLiabilitiesGross
31030000
CY2013Q2 psdv Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
353000
CY2013Q2 psdv Estimated Annual Amortization Of Intangible Assets
EstimatedAnnualAmortizationOfIntangibleAssets
760000
CY2013Q2 psdv Warrants Outstanding Weighted Average Remaining Contract Life
WarrantsOutstandingWeightedAverageRemainingContractLife
P3Y4M24D
CY2013Q2 psdv Cash Equivalents Fair Value Disclosure
CashEquivalentsFairValueDisclosure
6330000
CY2013Q2 psdv Cash And Cash Equivalents And Marketable Securities Fair Value
CashAndCashEquivalentsAndMarketableSecuritiesFairValue
10300000
CY2013Q2 psdv Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
1000
CY2013Q2 psdv Milestone Payment Due Upon Approval
MilestonePaymentDueUponApproval
25000000
CY2012 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1104000
CY2013Q2 psdv Collaboration Agreement Ownership Percentage In Company
CollaborationAgreementOwnershipPercentageInCompany
0.080 pure
us-gaap Fair Value Inputs Control Premium
FairValueInputsControlPremium
0.15 pure
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
14830000
CY2011Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2210000 shares
CY2011Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1000000
CY2011Q1 psdv Percentage Of Shares Of Common Stock Issued Under Terms Of Warrant Transactions
PercentageOfSharesOfCommonStockIssuedUnderTermsOfWarrantTransactions
0.25 pure
CY2011Q1 psdv Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
11050000
CY2011Q1 psdv Term Of Warrants
TermOfWarrants
P5Y
CY2011Q1 psdv Warrants Granted To Purchase Common Stock
WarrantsGrantedToPurchaseCommonStock
552500 shares
CY2011Q1 psdv Share Price Per Unit
SharePricePerUnit
5.00
CY2012Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2494419 shares
CY2012Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000
CY2012Q3 psdv Percentage Of Shares Of Common Stock Issued Under Terms Of Warrant Transactions
PercentageOfSharesOfCommonStockIssuedUnderTermsOfWarrantTransactions
0.25 pure
CY2012Q3 psdv Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
5400000
CY2012Q3 psdv Term Of Warrants
TermOfWarrants
P5Y
CY2012Q3 psdv Warrants Granted To Purchase Common Stock
WarrantsGrantedToPurchaseCommonStock
623605 shares
CY2012Q3 psdv Share Price Per Unit
SharePricePerUnit
2.15
CY2012Q3 psdv Class Of Warrant Or Right Period From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable
2013-02
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19489000 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3170000
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0113 pure
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10561122 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0235 pure
CY2011 us-gaap Revenues
Revenues
4965000
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7720000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8846000
CY2011 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
15963000
CY2011 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-11000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-3327000
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5519000
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000
CY2011 us-gaap Income Taxes Paid
IncomeTaxesPaid
56000
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
30000
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-10003000
CY2011 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-285000
CY2011 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
919000
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1157000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-8628000
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
908000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2052000
CY2011 us-gaap Royalty Revenue
RoyaltyRevenue
1353000
CY2011 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
106000
CY2011 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10043000
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
133000
CY2011 us-gaap License And Services Revenue
LicenseAndServicesRevenue
3612000
CY2011 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1140000
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8104000
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10060000
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3045000
CY2011 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-209000
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
880000
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
2052000
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2602000
CY2011 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
449000
CY2011 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
146000
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-350000
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-64000
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10043000
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3008000
CY2011 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-209000
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9498000
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6864000
CY2011 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000
CY2011 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-113000
CY2011 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3302000
CY2011 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-105000
CY2011 us-gaap Depreciation
Depreciation
53000
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2052000
CY2011 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
CY2011 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6598000
CY2011 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
228000
CY2011 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
96000
CY2011 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
-105000
CY2011 us-gaap Operating Expenses
OperatingExpenses
14968000
CY2011 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
189000
CY2011 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-27000
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-218000
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
6000
CY2011 psdv Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
36000
CY2011 psdv Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
160000
CY2013 dei Entity Registrant Name
EntityRegistrantName
pSivida Corp.
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2013 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Operations</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">pSivida Corp. (together with its subsidiaries, the &#x201C;Company&#x201D;), incorporated in Delaware, develops tiny, sustained-release products designed to deliver drugs and biologics at a controlled and steady rate for weeks, months or years. Using its core technology platforms, Durasert&#x2122; and BioSilicon&#x2122;, the Company is focused on treatment of chronic diseases of the back of the eye and is also exploring applications outside ophthalmology. The Company has developed three of the four sustained-release products for treatment of retinal diseases currently approved in the U.S. or European Union (&#x201C;EU&#x201D;), and its lead product candidate began a Phase III clinical trial in the fiscal 2013 fourth quarter. The Company&#x2019;s strategy includes developing products independently while continuing to leverage its technology platforms through collaboration and license agreements.</font></p> <p style="PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>ILUVIEN</i><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline">&#xAE;</sup></font>, the Company&#x2019;s most recently approved product, is an injectable, sustained-release micro-insert that provides treatment of vision impairment associated with chronic diabetic macular edema (&#x201C;DME&#x201D;) considered insufficiently responsive to available therapies over a period of up to three years. ILUVIEN is licensed to and sold by Alimera Sciences, Inc. (&#x201C;Alimera&#x201D;), and the Company is entitled to a share of the net profits, as defined, from Alimera&#x2019;s sales of ILUVIEN for DME. Alimera commenced the commercial launch of ILUVIEN for DME in the United Kingdom and Germany in the second quarter of 2013 and expects to launch in France in the first quarter of 2014. Alimera is also seeking marketing approval for ILUVIEN for DME in the U.S. In the second quarter of 2013, Alimera received a new Prescription Drug User Fee Act (&#x201C;PDUFA&#x201D;) goal date of October&#xA0;17, 2013 after resubmitting its New Drug Application (&#x201C;NDA&#x201D;) for ILUVIEN for DME. The resubmission responded to a second Complete Response Letter (&#x201C;CRL&#x201D;) received from the U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) in November 2011.</font></p> <p style="PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Medidur</i>&#x2122;, the Company&#x2019;s lead development product, commenced the first of two planned pivotal Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (&#x201C;posterior uveitis&#x201D;) in June 2013. Medidur uses the same Durasert micro-insert used in ILUVIEN and delivers a lower dose of the same drug as the Company&#x2019;s FDA-approved Retisert<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline">&#xAE;</sup></font> for posterior uveitis. The Company is developing Medidur independently.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company is also developing a bioerodible, injectable micro-insert delivering latanoprost (the &#x201C;Latanoprost Product&#x201D;) to treat glaucoma and ocular hypertension. Under an amended collaboration agreement, Pfizer has an option, under certain circumstances, to license the development and commercialization of the Latanoprost Product worldwide.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company is engaged in pre-clinical research with respect to both its BioSilicon and Durasert technology platforms. The primary focus of the BioSilicon technology research is the sustained delivery, using Tethadur&#x2122;, of peptides, proteins, antibodies and other large biologic molecules in both ophthalmic and non-ophthalmic applications. The Company&#x2019;s research program also includes the use of Durasert technology in orthopedic applications and for systemic delivery of therapeutic agents.</font></p> <p style="PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s FDA-approved product <i>Retisert</i><font style="FONT-FAMILY: Times New Roman" size="1"><sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline">&#xAE;</sup></font> provides sustained release treatment of posterior uveitis for approximately two and a half years and is licensed to and sold by Bausch&#xA0;&amp; Lomb.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company has a history of operating losses and has financed its operations primarily from the proceeds of sales of its equity securities and the receipt of license fees, research and development funding, royalties and contingent cash payments from its collaboration partners. The Company believes that its cash, cash equivalents and marketable securities of $10.3 million at June&#xA0;30, 2013, together with $9.9 million of net proceeds received from an underwritten public offering of common shares in July 2013 and expected Retisert royalty income and other expected cash inflows under existing collaboration agreements, will enable the Company to maintain its current and planned operations through calendar year 2014. This includes expected costs through that date of Phase III clinical trials of the posterior uveitis micro-insert, but excludes any potential milestone or net profit receipts under the Alimera collaboration agreement. The Company&#x2019;s financial resources could be significantly improved if ILUVIEN for DME is approved by the FDA, which would entitle the Company to a $25.0 million milestone payment, or if Alimera successfully commercializes ILUVIEN for DME in the EU or, if approved, in the U.S. The Company&#x2019;s ability to fund its planned operations beyond 2014, including completion of planned Phase III trials of the posterior uveitis micro-insert, is expected to depend on the amount and timing of cash receipts under existing collaboration agreements, as well as any future collaboration or other agreements and/or financing transactions.</font></p> </div>
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8745000
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.98 pure
CY2013 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2014-04-06
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001314102
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0081 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23044000 shares
CY2013 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.95 pure
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentrations of Risk</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. At June&#xA0;30, 2013, all of the Company&#x2019;s interest-bearing cash equivalent balances, aggregating $6.3 million, were concentrated in one institutional money market fund that has investments consisting primarily of certificates of deposit, commercial paper, time deposits, U.S. government agency securities, treasury bills and treasury repurchase agreements. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. Marketable securities at June&#xA0;30, 2013 consist of investment-grade corporate bonds and commercial paper. The Company&#x2019;s investment policy, approved by the Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Pfizer accounted for $368,000, or 17%, of total revenues in fiscal 2013, $754,000, or 21%, of total revenues in fiscal 2012 and $3.3 million, or 67%, of total revenues in fiscal 2011. Bausch&#xA0;&amp; Lomb accounted for $1.4 million, or 64%, of total revenues in fiscal 2013, $1.4 million, or 41%, of total revenues in fiscal 2012 and $1.4 million, or 27%, of total revenues in fiscal 2011.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Bausch&#xA0;&amp; Lomb accounted for $316,000, or 53%, of total accounts receivable at June&#xA0;30, 2013 and $442,000, or 46%, of total accounts receivable at June&#xA0;30, 2012.</font></p> </div>
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4730654 shares
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2939000
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenues and expenses during the reporting periods. Significant management estimates and assumptions include, among others, those related to revenue recognition for multiple-deliverable arrangements, recoverability of intangible assets, realization of deferred tax assets and the valuation of stock option awards. Actual results could differ from these estimates.</font></p> </div>
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0098 pure
CY2013 us-gaap Revenues
Revenues
2143000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11922000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12017000
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7758000
CY2013 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
7000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1916000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-10101000
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
16000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-12031000
CY2013 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-364000
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-29000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-11900000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1317000
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
1363000
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
134000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4669000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
68000
CY2013 us-gaap License And Services Revenue
LicenseAndServicesRevenue
780000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7169000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4669000
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-712000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
35000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1317000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2274000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
454000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1288000
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-569000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
277000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4669000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4086000
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6358000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7005000
CY2013 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
769000
CY2013 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-117000
CY2013 us-gaap Depreciation
Depreciation
225000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1317000
CY2013 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
CY2013 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14184000
CY2013 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
145000
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2013 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
-117000
CY2013 us-gaap Operating Expenses
OperatingExpenses
14174000
CY2013 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
152000
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
882000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-117000
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-8000
CY2013 psdv Operating Lease Agreements Expiration Date
OperatingLeaseAgreementsExpirationDate
August 2016
CY2013 psdv Optional Termination Of Lease Expiration Date
OptionalTerminationOfLeaseExpirationDate
September 2014
CY2013 psdv Percentage Of Likelihood For Term More Likely Than Not
PercentageOfLikelihoodForTermMoreLikelyThanNot
0.50 pure
CY2013 psdv Milestone Payment Due Upon Approval By Fda
MilestonePaymentDueUponApprovalByFda
25000000
CY2013 psdv Defined Contribution Plans Employee Contribution Percentage Of Eligible Compensation Matched By Employer
DefinedContributionPlansEmployeeContributionPercentageOfEligibleCompensationMatchedByEmployer
0.05 pure
CY2013 psdv Income Tax Reconciliation Expiration Of Net Operating Loss Carry Forwards
IncomeTaxReconciliationExpirationOfNetOperatingLossCarryForwards
706000
CY2013 psdv Net Proceeds From Issuance Of Common Stock
NetProceedsFromIssuanceOfCommonStock
9900000
CY2013 psdv Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
1272000
CY2013 psdv Cash Equivalent Maturity Period Description
CashEquivalentMaturityPeriodDescription
Three months or less
CY2013 psdv Increase In Valuation Allowances And Reserves
IncreaseInValuationAllowancesAndReserves
2900000
CY2013 psdv Marketable Securities Maturity Period
MarketableSecuritiesMaturityPeriod
Greater than ninety days
CY2013 psdv Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
231000
CY2013 psdv Operating Lease Expiration Year
OperatingLeaseExpirationYear
2016
CY2013 psdv Defined Contribution Plan Employee Maximum Contribution Percentage
DefinedContributionPlanEmployeeMaximumContributionPercentage
0.15 pure
CY2013 psdv Operating Lease Early Termination Notice Period
OperatingLeaseEarlyTerminationNoticePeriod
P6M
CY2012 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P18D
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.88 pure
CY2012 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.90 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20791000 shares
CY2012 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0003 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9001000
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.19
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.97 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0053 pure
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5436044 shares
CY2012 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0202 pure
CY2012 us-gaap Revenues
Revenues
3526000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25322000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25004000
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
15392000
CY2012 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
5000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-13789000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-11215000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
114000
CY2012 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
38000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-25211000
CY2012 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
128000
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-492000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
207000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-24835000
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-487000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1411000
CY2012 us-gaap Royalty Revenue
RoyaltyRevenue
1446000
CY2012 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
156000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
405000
CY2012 us-gaap License And Services Revenue
LicenseAndServicesRevenue
2080000
CY2012 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
170000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6868000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
114000
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7500000
CY2012 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
14830000
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-13000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1895000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
1411000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8287000
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-599000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
64000
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22294000 shares
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-6000
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8501000
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-13000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
606000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7039000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
114000
CY2012 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-13000
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2037000
CY2012 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-156000
CY2012 us-gaap Depreciation
Depreciation
190000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1411000
CY2012 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
CY2012 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
15299000
CY2012 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1163000
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2012 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
-156000
CY2012 us-gaap Operating Expenses
OperatingExpenses
28737000
CY2012 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
264000
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
424000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-169000
CY2012 psdv Outstanding Australian Warrants Expiration Date
OutstandingAustralianWarrantsExpirationDate
July 19, 2012
CY2012 psdv Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
44000
CY2012 psdv Increase In Valuation Allowances And Reserves
IncreaseInValuationAllowancesAndReserves
7500000
CY2012 psdv Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
181000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23297000 shares
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2013Q1 us-gaap Revenues
Revenues
513000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2812000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-2794000
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20803000 shares
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2012Q1 us-gaap Revenues
Revenues
538000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2727000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-2686000
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20803000 shares
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2012Q2 us-gaap Revenues
Revenues
699000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2310000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-2262000
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23297000 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2013Q2 us-gaap Revenues
Revenues
492000
CY2012Q3 us-gaap Revenues
Revenues
553000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3981000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-3947000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2590000
CY2012Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23297000 shares
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2012Q4 us-gaap Revenues
Revenues
585000
CY2012Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2648000
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-2608000
CY2011Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20757000 shares
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2011Q3 us-gaap Revenues
Revenues
1659000
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2531000
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-2427000
CY2011Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1100000
CY2011Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20803000 shares
CY2011Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2011Q4 us-gaap Revenues
Revenues
630000
CY2011Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-17643000
CY2011Q4 us-gaap Net Income Loss
NetIncomeLoss
-17460000
CY2011Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
14800000

Files In Submission

Name View Source Status
0001193125-13-382009-index-headers.html Edgar Link pending
0001193125-13-382009-index.html Edgar Link pending
0001193125-13-382009.txt Edgar Link pending
0001193125-13-382009-xbrl.zip Edgar Link pending
d578881d10k.htm Edgar Link pending
d578881dex211.htm Edgar Link pending
d578881dex231.htm Edgar Link pending
d578881dex311.htm Edgar Link pending
d578881dex312.htm Edgar Link pending
d578881dex321.htm Edgar Link pending
d578881dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
psdv-20130630.xml Edgar Link completed
psdv-20130630.xsd Edgar Link pending
psdv-20130630_cal.xml Edgar Link unprocessable
psdv-20130630_def.xml Edgar Link unprocessable
psdv-20130630_lab.xml Edgar Link unprocessable
psdv-20130630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R40.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R41.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R42.xml Edgar Link unprocessable
R43.htm Edgar Link pending
R43.xml Edgar Link unprocessable
R44.htm Edgar Link pending
R44.xml Edgar Link unprocessable
R45.htm Edgar Link pending
R45.xml Edgar Link unprocessable
R46.htm Edgar Link pending
R46.xml Edgar Link unprocessable
R47.htm Edgar Link pending
R47.xml Edgar Link unprocessable
R48.htm Edgar Link pending
R48.xml Edgar Link unprocessable
R49.htm Edgar Link pending
R49.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R50.htm Edgar Link pending
R50.xml Edgar Link unprocessable
R51.htm Edgar Link pending
R51.xml Edgar Link unprocessable
R52.htm Edgar Link pending
R52.xml Edgar Link unprocessable
R53.htm Edgar Link pending
R53.xml Edgar Link unprocessable
R54.htm Edgar Link pending
R54.xml Edgar Link unprocessable
R55.htm Edgar Link pending
R55.xml Edgar Link unprocessable
R56.htm Edgar Link pending
R56.xml Edgar Link unprocessable
R57.htm Edgar Link pending
R57.xml Edgar Link unprocessable
R58.htm Edgar Link pending
R58.xml Edgar Link unprocessable
R59.htm Edgar Link pending
R59.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R60.htm Edgar Link pending
R60.xml Edgar Link unprocessable
R61.htm Edgar Link pending
R61.xml Edgar Link unprocessable
R62.htm Edgar Link pending
R62.xml Edgar Link unprocessable
R63.htm Edgar Link pending
R63.xml Edgar Link unprocessable
R64.htm Edgar Link pending
R64.xml Edgar Link unprocessable
R65.htm Edgar Link pending
R65.xml Edgar Link unprocessable
R66.htm Edgar Link pending
R66.xml Edgar Link unprocessable
R67.htm Edgar Link pending
R67.xml Edgar Link unprocessable
R68.htm Edgar Link pending
R68.xml Edgar Link unprocessable
R69.htm Edgar Link pending
R69.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R70.htm Edgar Link pending
R70.xml Edgar Link unprocessable
R71.htm Edgar Link pending
R71.xml Edgar Link unprocessable
R72.htm Edgar Link pending
R72.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending